MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 

Location: Categories / Business / Industries / Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.
Old Articles: <Older 7901-7910 Newer>
The Motley Fool
September 28, 2011
Alex Dumortier
Edwards Lifesciences: Creating or Destroying Value? With shares trading at 33.2 times its earnings-per-share estimate for the next 12 months, the share buyback program looks like a poor use of shareholder capital at these prices. mark for My Articles 156 similar articles
The Motley Fool
September 27, 2011
Brian Orelli
Promising Results, But It's Still Early Aeterna Zentaris' investors got a bit of good news yesterday while they wait for phase 3 data for the company's colorectal cancer drug perifosine. mark for My Articles 272 similar articles
Registered Rep.
September 26, 2011
Stan Luxenberg
Despite Ill Winds, Health Stocks Look Healthy Health stock valuations look compelling, and many companies should report solid earnings growth. mark for My Articles 312 similar articles
The Motley Fool
September 26, 2011
Brian Orelli
Closer to Approval, Now Can MELA Find Customers? The restrictions might be too much. The company has been fighting for years to gain Food and Drug Administration approval of its melanoma detection device, MelaFind. mark for My Articles 92 similar articles
The Motley Fool
September 23, 2011
Michael Olsen
1 Special Stock Pick From an Outside View Don't fall prey to market myopia. We expect contract researchers -- like Charles River, Icon, and Pharmaceutical Product Development -- to benefit as pharmaceutical companies adopt an increasingly cost-conscious posture. mark for My Articles 16 similar articles
The Motley Fool
September 23, 2011
Brian Orelli
Matching Supply and Demand Is Easier Said Than Done Pac Bio cuts its workforce due to lower-than-expected demand. mark for My Articles 104 similar articles
The Motley Fool
September 21, 2011
Brian Orelli
Obesity-Drug Makers Stop Getting Bullied The drugs are still relative long shots being developed by companies that may have to raise more cash between now and an approval. mark for My Articles 270 similar articles
The Motley Fool
September 21, 2011
One Hot Stock to Avoid Our investing community's latest prime pick to avoid: MELA Sciences. mark for My Articles 18 similar articles
The Motley Fool
September 21, 2011
Luke Timmerman
Orexigen Revives Obesity Drug After One More Go-Round With FDA Orexigen has new life. mark for My Articles 236 similar articles
The Motley Fool
September 21, 2011
Seth Jayson
How Long Does It Take to Make a Buck at Merck? With quarterly CCC doing worse than average and the latest 12-month CCC coming in better, Merck gets a mixed review in this cash-conversion checkup. mark for My Articles 625 similar articles
<Older 7901-7910 Newer>    Return to current articles.